Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented Phase 1 clinical data for LFD-200 at the American College of Rheumatology (ACR) Convergence 2026 conference. LFD-200 is a novel subcutaneously administered ADC that delivers a potent glucocorticoid directly to immune cells. The data from healthy participants showed that LFD-200 was well tolerated, produced dose-responsive anti-inflammatory effects, and did not affect serum cortisol, a sensitive marker for systemic glucocorticoid toxicity.
The significance of these findings lies in the potential to separate the anti-inflammatory benefits of glucocorticoids from their systemic side effects. Glucocorticoids are widely used to treat autoimmune conditions but carry risks such as adrenal suppression, osteoporosis, and metabolic disturbances when given systemically. By targeting the drug to immune cells, LFD-200 aims to provide potent anti-inflammatory activity while sparing patients from these toxicities. The absence of cortisol suppression in the Phase 1 trial supports this hypothesis and suggests a favorable safety profile.
Lifordi also announced that dosing in patients with moderate to severe rheumatoid arthritis is ongoing in a Phase 1b study, with initial data anticipated by the end of 2026. These patient data will be critical to determining whether the promising healthy-volunteer results translate into clinical benefit for people living with RA, a chronic autoimmune disease affecting millions worldwide. If successful, LFD-200 could offer a new treatment option that avoids the burdens of long-term systemic steroid use.
The company’s approach extends beyond glucocorticoids. Lifordi has applied its drug delivery platform to other payloads, including antisense oligonucleotides, siRNA, and small molecules, suggesting potential applications across a broad range of immune and inflammatory diseases. The company is backed by ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, and is led by experienced drug developers in immunology and inflammatory diseases.
For those following the autoimmune therapeutics space, Lifordi’s progress with LFD-200 represents a notable step toward more targeted, safer anti-inflammatory treatments. The full announcement, including downloadable images and bios, is available click here. More information about the company can be found at www.lifordi.com. The data were presented at ACR Convergence 2026, a key venue for rheumatology research, underscoring the potential impact of these findings on the treatment landscape for rheumatoid arthritis and other autoimmune disorders.
